KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Prepaid Assets (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Prepaid Assets for 11 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 18.5% to $9.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Dec 2025, up 18.5% year-over-year, with the annual reading at $9.8 million for FY2025, 18.5% up from the prior year.
  • Prepaid Assets hit $9.8 million in Q4 2025 for CRISPR Therapeutics AG, down from $13.4 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $41.7 million in Q2 2022 to a low of $8.2 million in Q3 2024.
  • Historically, Prepaid Assets has averaged $22.9 million across 5 years, with a median of $21.1 million in 2023.
  • Biggest five-year swings in Prepaid Assets: surged 79.93% in 2021 and later tumbled 61.85% in 2023.
  • Year by year, Prepaid Assets stood at $38.1 million in 2021, then dropped by 0.97% to $37.7 million in 2022, then crashed by 61.85% to $14.4 million in 2023, then tumbled by 42.26% to $8.3 million in 2024, then grew by 18.5% to $9.8 million in 2025.
  • Business Quant data shows Prepaid Assets for CRSP at $9.8 million in Q4 2025, $13.4 million in Q3 2025, and $12.4 million in Q2 2025.